The United Kingdom and the United States have finalized a landmark bilateral deal that will guarantee zero tariffs on British drug products being sold in the US market.
Key Provisions of the Accord
As part of the deal, the UK has pledged to raise spending on medicines through the NHS. This pledge secures that import taxes on these vital products will stay at nothing for a period of 36 months.
This deal comes after previous warnings to significantly raise import taxes on patented pharmaceutical imports, with potential rates floated up to 100%.
"This deal with the UK strengthens the worldwide climate for innovative medicines and brings long-overdue fairness to American-British drug exports," a statement declared.
Commercial Importance
Medicines represent one of the Britain's largest goods shipped to the US, which is clearly the biggest market for leading UK drugmakers.
Statistics show that in the year prior to last September, the UK sold drugs totaling over eleven billion pounds to the US. This amount accounted for 17.4% of British export trade in that timeframe.
"This guarantee protects work, boosts capital expenditure and paves the way for the UK to emerge as a international leader for biotech and pharma," the Business and Trade Secretary stated.
Key NHS Changes
The pact includes several specific changes from the United Kingdom:
- Price Threshold Increase: The UK will increase the price threshold at which it deems new medicines to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a aim to increase overall public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years.
- Rebate Cap: The percentage pharmaceutical firms must refund to the NHS to stay within budget will be limited at 15%. In the past, refunds were more than 20%.
Recent Tensions
The deal follows a ongoing tension between the drug companies and the British authorities over drug pricing and regulatory access.
This friction were heightened by claims that American consumers were paying a premium for the identical medicines than people in the UK and Europe.
In recent months, several large manufacturing plans in the UK have been delayed or scrapped, while substantial expansions have been pledged toward projects in the United States.
One official publicly accepted that the NHS must invest a greater share on treatments, noting that its expenditure on drugs had declined as a share of its overall budget over the past decade.
